Manchester First in U.S. to Launch Pharmacy, Pharmacogenomics Dual Degree

Posted: Updated:
Students can now simultaneously earn a pharmacogenomics master’s degree alongside the Doctor of Pharmacy (Pharm.D.) degree. Students can now simultaneously earn a pharmacogenomics master’s degree alongside the Doctor of Pharmacy (Pharm.D.) degree.

No other pharmacy graduates in the nation will have credentials quite like those from Manchester University, says Director of Pharmacogenomics Education Dr. David Kisor. The small liberal arts school in northern Indiana says it’s the first in the U.S. to offer a dual degree in pharmacy and pharmacogenomics—a relatively new area in healthcare hungry for experts. Kisor believes the dual doctor of pharmacy and master of pharmacogenomics program is a “differentiator” for the school, its students and—most importantly—patients who could be spared a dangerous dose of medicine.

“In 2017, there were almost 2 million adverse drug reactions, and of those, more than 800,000 were serious adverse drug reactions, meaning a patient needed to be treated or see a healthcare provider because of a drug reaction,” says Kisor, who is also a professor of pharmaceutical sciences. “There were more than 160,000 deaths in 2017 due to adverse drug reactions, and many of these can be related to an individual’s genetics.”

Kisor says pharmacogenomics is a powerful antidote to adverse drug reactions. The relatively new area of study involves analyzing the patient’s genetic makeup, then prescribing medication tailored for that individual. A drug that works for one person may, for example, cause an adverse reaction in another individual with the same disease, due to their unique genotype.

The American Council on Pharmaceutical Education didn’t begin requiring schools to teach pharmacogenomics until 2016. That year, Manchester was the first pharmacy school in the nation to launch a master’s degree in pharmacogenomics. The university says technology that analyzes a person’s genetic makeup has since exploded, making the information readily available.

“[Pharmacogenomics] is the next way to prescribe medicine. It’s a much more personalized approach,” says Manchester Assistant Professor of Pharmaceutical Sciences and Pharmacogenomics Dr. Diane Calinski. “It’s tailored to the patient, so overall, it has better health outcomes for the patient and [reduces costs] in our healthcare system. Pharmacogenomics is the future of medicine, so we recognize that it’s important to emphasize that in our pharmacy education.”

St. Jude Children’s Research Hospital in Tennessee, for example, now performs pharmacogenomics testing for every patient. But Kisor says, nationally, training programs have struggled to provide experts at the same pace the field is expanding.

Manchester leaders believe the new dual degree program, the first of its kind in the U.S., will swell the number of pharmacogenomics experts. Traditionally, schools offer four-year professional Doctor of Pharmacy (Pharm.D.) degrees; while Manchester will continue its conventional Pharm.D. program, students can now simultaneously earn a pharmacogenomics master’s degree.

“They can finish…in the four years that it takes to do just the Pharm.D. alone,” says Calinski. “They’re here for the same amount of time, but when they finish, they have two degrees instead of one.”

Manchester says it admits more than 70 pharmacy students each year, and currently, 10 have applied for the dual degree program; Calinski expects that number to grow to about 15.

Ellen Line is a first-year Pharm.D. student at Manchester who plans to enroll in the dual degree program; she says pharmacogenomics is something “pharmacists will need to know to excel in the field.”

“I thought to myself, four years from now when I do get a pharmacy position, I’m going to wish I had [the pharmacogenomics expertise],” says Line. “I don’t want to have to go back to school after I’ve already found a job. I’d rather do it now and learn both things at the same time, before I even go into the pharmacy profession.”

Kisor believes Manchester’s pharmacogenomics master’s program and dual degree set the university apart; while the other two pharmacy schools in the state, Butler University and Purdue University, teach pharmacogenomics, Manchester is the only one with a master’s program.

“We’re just ahead of the curve, I think. There’s no template or standard, so in many ways, we’re setting the standard,” says Kisor.  “We’ll be the first to graduate capable pharmacogenomics experts. The real visionaries are the students coming into these programs, because right now, there’s no defined standard job for these graduates; they’re going to go out there and create these jobs—from community pharmacies to large medical centers. And patients are going to benefit.” 

While adverse drug reactions are more dangerous, Kisor says drug inefficacy is an additional issue that causes patient suffering and unnecessary healthcare costs.
Kisor expects the dual degree program to at least double the number of pharmacists in the U.S. with pharmacogenomics expertise.
Line says she’s excited to be among the first pharmacists in the country with pharmacogenomics expertise.
  • Perspectives

    • Job Insights For The Third Quarter

      To provide accurate and timely employment forecasts for business leaders, Express Employment Professionals International Headquarters conducts an ongoing Job Insights survey to track quarterly hiring trends across a wide range of industries. Express surveyed business owners, decision makers, and human resource professionals about the overall hiring trends in their markets and how they impact their hiring decisions. Overall confidence remains high going into the second half of 2018.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • Purdue Professor, Wife Indicted For Fraud

      A Purdue University professor and his wife have been indicted on federal fraud charges. U.S. Attorney Thomas Kirsch's office says Qingyou Han and Lu Shao are accused of hatching a scheme to defraud the National Science Foundation. 

    • Maureen Krauss (pictured left) is chief economic development officer at the Indy Chamber and Tom Leinbarger (pictured right) is chief executive officer at Cummins Inc.

      Indiana Businesses Fret Potential Trade War

      As a potential trade war looms over recently-imposed tariffs on China, Indiana businesses are expressing concern about the fallout. It is estimated that global trade supports more than 800,000 jobs in Indiana, many of those in the manufacturing and agriculture sectors. In 2016, Columbus-based Cummins Inc. sold more than 500,000 engines in China. Chief Executive Officer Tom Linebarger says the company's global footprint generates jobs and investment in Indiana.

    • Devour Indy Restaurants Unveiled

      Devour Indy has released the list of restaurants participating in the Summerfest 2018 event, which kicks off next month. More than 100 Indianapolis-area restaurants are participating this year, including more than 10 new additions to the list. 

    • The fund was first announced as part of Holcomb's Next Level Agenda. (Image courtesy of the state of Indiana.)

      Next Level Fund Makes First Investments

      Governor Eric Holcomb’s office says the Next Level Indiana Trust Fund has made its first two funding commitments. The fund, created by the Indiana General Assembly in 2017, has awarded a total of $21.5 million to Indianapolis-based High Alpha Capital and Colorado-based Foundry Group.

    • Walmart Details Crawfordsville Layoffs

      Walmart Inc. (NYSE: WMT) is reducing workforce at the Walmart Optical Lab in Crawfordsville. In a notice to the state, the company said 108 employees will be out of work by the end of September. A corporate spokeswoman told Inside INdiana Business the decision was a response to "changing business needs." She added "we are making adjustments at our Walmart Optical Labs in Crawfordsville to help ensure we have the right people in the right place at the right time."